A Multicentre, Open-Label, Repeated Measures, Phase 2a Clinical Pilot Trial
Background
Since the 1990’s attempts to favorably modulate nitric oxide (NO) have been unsuccessful. We hypothesized that because NO is lipophilic it would preferentially localize into intravascularly infused hydrophobic nanoparticles, thereby reducing its bioavailability and adverse effects without inhibiting its production. We aimed to determine the efficacy and safety of intravenous infusion of a fluid comprised of hydrophobic phospholipid nanoparticles (VBI-S) that reversibly absorb NO in the treatment of hypotension of patients in severe septic shock.
Published: January 29, 2024
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00009-9/fulltext